| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1091230059 |
| P356 | DOI | 10.1038/S41598-017-08909-8 |
| P932 | PMC publication ID | 5562737 |
| P698 | PubMed publication ID | 28821780 |
| P50 | author | Elaine Lai-Han Leung | Q107644494 |
| P2093 | author name string | Ying Li | |
| Qianqian Wang | |||
| Liang Liu | |||
| Yuwei Wang | |||
| Xiaojun Yao | |||
| Jiahui Xu | |||
| P2860 | cites work | Structure and ligand of a histone acetyltransferase bromodomain | Q22009928 |
| The bromodomain protein Brd4 insulates chromatin from DNA damage signalling | Q24294320 | ||
| Selective inhibition of BET bromodomains | Q24301009 | ||
| Histone recognition and large-scale structural analysis of the human bromodomain family | Q24310431 | ||
| The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p | Q24596953 | ||
| Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression | Q27647088 | ||
| Cooperative binding of two acetylation marks on a histone tail by a single bromodomain | Q27657619 | ||
| Discovery and characterization of small molecule inhibitors of the BET family bromodomains | Q27667834 | ||
| Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family | Q27675927 | ||
| RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain | Q27680635 | ||
| Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression | Q27684429 | ||
| Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials | Q27703736 | ||
| RVX-297- a novel BD2 selective inhibitor of BET bromodomains | Q27709485 | ||
| Lysine acetylation targets protein complexes and co-regulates major cellular functions | Q27860589 | ||
| Targeting bromodomains: epigenetic readers of lysine acetylation | Q28238635 | ||
| Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations | Q28818600 | ||
| Development and testing of a general amber force field | Q29547642 | ||
| Epigenetic protein families: a new frontier for drug discovery | Q29616621 | ||
| Targeting MYC dependence in cancer by inhibiting BET bromodomains | Q29617196 | ||
| Molecular Dynamics Simulations and Structural Network Analysis of c-Abl and c-Src Kinase Core Proteins: Capturing Allosteric Mechanisms and Communication Pathways from Residue Centrality. | Q30009131 | ||
| Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling | Q50591561 | ||
| Does bromodomain flexibility influence histone recognition? | Q50957600 | ||
| Structure-based virtual screening of novel, high-affinity BRD4 inhibitors | Q57163250 | ||
| Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity | Q84993045 | ||
| Binding Kinetics versus Affinities in BRD4 Inhibition | Q85890063 | ||
| Tuning the smooth particle mesh Ewald sum: application on ionic solutions and dipolar fluids | Q85967243 | ||
| Directly Binding Rather than Induced-Fit Dominated Binding Affinity Difference in (S)- and (R)-Crizotinib Bound MTH1 | Q87074532 | ||
| Van der Waals interactions dominate ligand-protein association in a protein binding site occluded from solvent water. | Q30351253 | ||
| Ligand binding and circular permutation modify residue interaction network in DHFR. | Q33287881 | ||
| Inhibition of BET bromodomain targets genetically diverse glioblastoma | Q34231228 | ||
| PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains | Q34338531 | ||
| Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations | Q34531578 | ||
| Residues crucial for maintaining short paths in network communication mediate signaling in proteins | Q35193500 | ||
| Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision | Q35208927 | ||
| Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism | Q35509663 | ||
| Small molecule inhibitors of bromodomain-acetyl-lysine interactions | Q35535791 | ||
| Histone H4 acetylation required for chromatin decompaction during DNA replication | Q35902773 | ||
| Interaction Networks in Protein Folding via Atomic-Resolution Experiments and Long-Time-Scale Molecular Dynamics Simulations | Q36288790 | ||
| Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins | Q36436791 | ||
| ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. | Q36766916 | ||
| Targeting BET bromodomain proteins in solid tumors | Q37619860 | ||
| OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations | Q37705651 | ||
| Bromodomains as therapeutic targets | Q37935915 | ||
| Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology. | Q38837561 | ||
| Picosecond to Millisecond Structural Dynamics in Human Ubiquitin | Q38880825 | ||
| Molecular mechanism of the inhibition and remodeling of human islet amyloid polypeptide (hIAPP(1-37)) oligomer by resveratrol from molecular dynamics simulation | Q39078203 | ||
| An atomistic view of Hsp70 allosteric crosstalk: from the nucleotide to the substrate binding domain and back | Q39646671 | ||
| RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. | Q40003658 | ||
| NAPS: Network Analysis of Protein Structures | Q41723625 | ||
| Genome-Wide Screen of Human Bromodomain-Containing Proteins Identifies Cecr2 as a Novel DNA Damage Response Protein | Q41864428 | ||
| Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites | Q41992499 | ||
| Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. | Q42707919 | ||
| The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21. | Q48850399 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8857 | |
| P577 | publication date | 2017-08-18 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations | |
| P478 | volume | 7 |
| Q47400790 | A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations. |
| Q52353697 | Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening |
Search more.